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diabetics 30%) with CTO treated with BVS were enrolled. A total of 63
BVS were implanted with the average number of 1.6 per patient, and
the scaffold length of 42.4  21.5 mm. Mean J-CTO score was 1.6.
Antegrade approach was used in 38 patients (95%), and retrograde,
after failed antegrade, in the remaining two (5%). High pressure post-
dilatation was performed in 38 patients. Procedural success was
achieved in all patients with no device-related complications. IVUS
was used in two, whereas OCT in ten patients. On QCA the mean in-
scaffold ﬁnal MLD was 2.13  0.31 mm and residual stenosis 13.90 
7.59%. In OCT analysis, performed in 10 patients, the minimal in-
scaffold luminal diameter was 2.65  0.45 mm, minimal luminal area
6.15  0.20 mm2, and lumen area stenosis 17.7  11.1%. At follow-up
(median time 434 days), there were no deaths, one patient experi-
enced subacute and late scaffold thrombosis (ST), another one
developed symptomatic in-scaffold focal restenosis treated with
repeat PCI. At control angiography, performed at the median time of
264 days in 23 patients (58%), the mean in-scaffold diameter stenosis
was 22.42  12.74, and the mean late lumen loss was 0.24  0.55 mm.
No more restenosis or vessel reocclusion was found.
CONCLUSIONS Stenting of coronary CTO lesions with bioresorbable
everolimus-eluting scaffolds is feasible with excellent acute perfor-
mance and good early and long-term clinical outcomes. Adequate
stenting technique and optimal DAPT is of crucial importance. The
results of our study represent a major step forward towards more
complete implementation of BVS to coronary interventions.
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BACKGROUND The bioresorbable vascular scaffold (BVS) is a new
therapy that provides transient vessel support with drug delivery
capability, potentially without the limitations of permanent metallic
implants. It can be an alternative option to currently used drug eluting
stents (DES) for percutaneous coronary intervention (PCI) of ischemic
coronary artery disease (CAD). We aimed to compare the non-inferi-
ority of BVS use to DES.
METHODS We searched Pub Med and Cochrane through June 2015 for
all randomized clinical trials (RCTs) that directly compared BVS and
DES for ischemic CAD. Primary outcome was target vessel revascu-
larization (TVR). Secondary outcomes included cardiac death, acute
myocardial infarction, and deﬁnite or probable stent thrombosis (ST).
We used Fixed or Random Effect analysis using the Cochrane Hand-
book of Systematic Reviews and RevMan 5.2 for statistical analysis.
RESULTS Out of 257 articles, four randomized trial studies were
included. The pooled data provided 3873 patients; 2024 treated with
BVS and 1849 with Everolimus drug-eluting stent. Mean follow up was
12 months. There was a trend towards lower TVR in BVS group
compared to Everolimus group (2.7% vs. 4.5%, p¼0.1) (Figure 1). There
was no difference in cardiac death (0.7 % vs. 0.7%, p¼0.8), AMI (3.4%
vs. 3.4%, p¼0.9) and ST (0.6% vs. 0.7%, p¼0.9) between the two
groups (Figure 2).CONCLUSIONS Our analysis showed similar outcomes between two
treatment modalities. This suggests that BVS might not be inferior to
DES for PCI of ischemic CAD. Further randomized trials should be
pursued to conﬁrm those ﬁndings.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bioabsorbable scaffolds, Drug-eluting stent, everolimus
TCT-525
Clinical outcomes following percutaneous coronary intervention using
small bioresorbable scaffolds
Akihito Tanaka,1 Azeem Latib,1 Neil Ruparelia,1 Hiroyoshi Kawamoto,1
Francesco Giannini,1 Alessandro Sticchi,1 Mauro Carlino,1
Alaide Chieffo,1 Matteo Montorfano,1 Antonio Colombo1
1San Raffaele Scientiﬁc Institute, Milan, Italy
BACKGROUND Bioresorbable scaffolds (BRS) are an attractive option
for the percutaneous treatment of coronary artery disease due to the
potential advantages associated with its complete absorption within
3-4 years of implantation. However, due the current design of BRS
with thicker struts compared to contemporary metallic stents, some
concern remains that this property may be associated with adverse
events including thrombosis and restenosis when using small BRS.
METHODS Among 350 consecutive lesions treated with Absorb BRS
during May 2012 – Apr 2015 at 2 high volume centers in Milan, 116
lesions were treated using 2.5 mm BRS (small BRS group) and 234
lesions were treated with BRS >2.5 mm BRS (large BRS group). Out-
comes including target lesion revascularization (TLR) per lesion and
deﬁnite stent thrombosis were investigated.
RESULTS The number of BRS was higher and the total BRS length was
longer in the small BRS group when compared to the large BRS group
(1.7  0.8 vs 1.4  0.6; p<0.001, and 42.3  22.6 mm vs 30.7  15.0mm;
p<0.001, respectively). As expected, the post procedural minimum
lumen diameter was signiﬁcantly smaller in the small BRS group (2.36
 0.43mm vs 2.82  0.44mm; p<0.001). TLR- free rate (median
